Business Wire

DAWEX

Share
Dawex Data Exchange Technology Addresses the European Data Act Future Principles of Regulated Data Circulation

With more than 80% of industrial data[1] remaining unused, the Data Act calls for the need of fundamental measures to regulate data circulation in order to make data more accessible for all. Granting consumers and companies the control over who accesses their data, for what purpose, is a pillar principle to future measures in order to unlock the richness of industrial data and build a regulated, fair European data economy. Dawex Data Exchange technology awards platform orchestrators the capability to keep control over the circulation of data through a secure, trusted data sharing and data exchange environment ensuring visibility of which data is being used, for which usage, under which terms.

In today’s economy where data has become a product with its own value, not limited to its usage, and the source of new revenue streams, Dawex technology allows organizations to create and gather new ecosystems around data exchange platforms that meet regulatory frameworks and addresses traceability and security challenges. Dawex is the leading technology company for data exchange , data marketplace and data hub , whose mission is to facilitate and accelerate secure data circulation between all economic stakeholders.

As the European Data Act stresses the critical importance of industrial data circulation in order to foster European data-driven innovation, Dawex technology has already demonstrated its operational and business value in more than 20 sectors such as agriculture, space, retail, agrifood, automotive, infrastructure, tourism, real estate and mobility by helping organizations in those industries address economical, social and environmental challenges.

The future Data Act is designed to harmonize rules on the fair access to and use of data generated in the EU across all economic sectors. The proposed measures encompass:

  • Facilitating access to generated IoT data to boost data-driven innovative services development,
  • Rebalancing SMEs’ negotiating power to prevent contractual misconducts in data exchange contracts,
  • Allowing public sector bodies access to data held by companies in public emergencies situations,
  • Defining new rules for data and cloud interoperability to simplify cloud and edge service providers switch,
  • Safeguarding unlawful data access and transfer by non-EU governments.

Dawex Data Exchange solution provides all the means and capabilities for data providers, data users and data exchange service providers to implement the future Data Act principles by delivering the high level of flexibility, traceability, and control available to all parties involved in data exchange. Data products can be clearly defined, accessed, and exchanged under flexible and fully configurable licensing terms, free of charge or against compensation.

“The Data Act’s ambition is to ensure a fair and innovative European data economy by making data more available for reuse to stimulate data-driven innovation.” said Laurent Lafaye, co-CEO at Dawex. “Since its inception, Dawex has been committed to delivering cutting-edge data exchange technology to bring the perfect conditions for secure and compliant data sharing. Dawex Data Exchange solutions are already aligned to what the Data Act proposes.”

Available in white label, Dawex Data Exchange, Data Hub and Data Marketplace solutions are today the only solutions on the market to offer such easy, efficient and highly secure data exchange capabilities.

“The development of Data Exchange technology facilitates the circulation of data between all economic stakeholders, supporting the flexible deployment of data ecosystems and their interconnection.” said Fabrice Tocco, Dawex co-CEO. “The European Data Act is another critical milestone that confirms Dawex vision and its technological direction for data exchange, driving a strong data economy.”

About Dawex

Dawex is the leading technology company for data exchange , data marketplace and data hub . Dawex mission is to facilitate and accelerate secure data circulation between economic stakeholders, institutions and private organizations, contributing to the development of the data economy. Awarded Technology Pioneer by the World Economic Forum, Dawex is a member of Gaia-X and a co-founding member of the Data Exchange Association . Created in 2015, Dawex has offices in France and Canada, expanding business operations to Asia, North America and the Middle East.

[1] Source: European Commission

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye